Mian, A., Wei, W., Chakraborty, R., Yi, J. C., Preussler, J. M., Hill, B. T., Cerny, J., Deol, A., Hahn, T. E., Hashmi, S. K., Jaglowski, S., Jim, H. S. L., Khera, N., Loren, A. W., McGuirk, J. P., Savani, B. N., Stiff, P., Uberti, J. P., Whalen, V., … Majhail, N. S. (2022). Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions. Blood, 140(Supplement 1), 8019–8021. https://doi.org/10.1182/blood-2022-167411

Fabrizio, V. A., Miller, K., Baggott, C., Prabhu, S., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Baumeister, S. H. C., Myers, G. D., Karras, N., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Wilcox, R., … Schultz, L. M. (2022). Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults. Blood, 140(Supplement 1), 4661–4663. https://doi.org/10.1182/blood-2022-169603

Lue, J. K., Stevens, D. A., Williams, M. E., Westin, J., Ewesuedo, R., McDonald, A., Agarwal, S., Henrick, P., Perea, R., & Gollob, J. (2022). Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140(Supplement 1), 12143–12144. https://doi.org/10.1182/blood-2022-170151

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153

Naqvi, S. A. A., Fatima, S., Asghar, N., Ijaz, H., Ayaz, A., He, H., Husnain, M., Chakraborty, R., Riaz, I., & Aljama, M. A. (2022). Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood, 140(Supplement 1), 10111–10113. https://doi.org/10.1182/blood-2022-170869

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C., Leventhal, J. R., Ho, B., Friedewald, J., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD. Blood, 140(Supplement 1), 3833–3834. https://doi.org/10.1182/blood-2022-167812

DeAngelo, D. J., Pullarkat, V. A., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Sachs, J., Sun, L., Pilla, A., Exter, B., Jolin, H. A., & Tashi, T. (2022). Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood, 140(Supplement 1), 1512–1513. https://doi.org/10.1182/blood-2022-156311

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3777–3778. https://doi.org/10.1182/blood-2022-160147

Mohyuddin, G. R., Chakraborty, R., Calip, G., Ascha, M. S., Wang, X., Rubinstein, S., Tuchman, S. A., Costa, L. J., Haaland, B., Giri, S., Mian, H. S., Fonseca, R., & Sborov, D. W. (2022). Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood, 140(Supplement 1), 5223–5224. https://doi.org/10.1182/blood-2022-165541

Balamurugan, M. A., Desiraju, S., Wojczyk, B. S., Namachivayam, K., Chung, Y., Guzman, P., & Krishnan, M. (2022). RBC Transfusion to Severe Anemic Murine Neonates Leads to Systemic Inflammation. Blood, 140(Supplement 1), 5702–5703. https://doi.org/10.1182/blood-2022-159574

Chakraborty, R., Sexton, R., Lentzsch, S., Abidi, M. H., Voorhees, P. M., Cohen, A. D., Rohren, E., Heitner, S. B., Kelly, K. R., Mackler, N. J., Baer, D. M., Hoering, A., Durie, B. G. M., Ailawadhi, S., & Orlowski, R. Z. (2022). Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib. Blood, 140(Supplement 1), 4349–4351. https://doi.org/10.1182/blood-2022-166609

Thomas, T., Qiu, A., Kim, C. Y., Gordy, D. E., Miller, A., Tredicine, M., Stone, E., Dzieciatkowska, M., Hod, E. A., D’Alessandro, A., Spitalnik, S. L., Zimring, J. C., Akpan, I. J., Luckey, C. J., & Hudson, K. E. (2022). Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels. Blood, 140(Supplement 1), 75–76. https://doi.org/10.1182/blood-2022-169746

Chen, Y.-B., Saad, A., Farhan, S. Y., Lekakis, L. J., Schiller, G. J., Yared, J. A., Assal, A., Lee, D. D., Lane, H., Gooley, T. A., & Defilipp, Z. (2022). RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation. Blood, 140(Supplement 1), 1877–1878. https://doi.org/10.1182/blood-2022-162512

Prince, H. M. M., Geskin, L. J., Akilov, O. E., Kuzel, T. M., Querfeld, C., Ooi, C. E., Xing, D., Sauter, N., Singh, P., Czuczman, M., & Foss, F. M. (2022). Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. Blood, 140(Supplement 1), 6577–6578. https://doi.org/10.1182/blood-2022-167564

Shah, N. N., Wang, M. L., Brown, J. R., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Gastinne, T., Ghia, P., Lamanna, N., Hoffmann, M., Patel, M. R., Flinn, I. W., Gerson, J. N., Ma, S., Coombs, C. C., … Mato, A. R. (2022). Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 4127–4132. https://doi.org/10.1182/blood-2022-159035

Molina, J. C., Chinnabhandar, V., Fabrizio, V. A., Kunicki, M., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Verneris, M. R., Myers, G. D., Karras, N., Baggott, C., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., Baumeister, S. H. C., … Smith, S. M. (2022). Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups. Blood, 140(Supplement 1), 10386–10388. https://doi.org/10.1182/blood-2022-165951

Batlevi, C. L., Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D., Campbell, P., McKay, P., Leonard, J. P., Sondhi, M., Chen, Y., Slatcher, P. L., Lin, R., Szanto, A., Abbadi, S., & Morschhauser, F. (2022). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1. Blood, 140(Supplement 1), 2296–2298. https://doi.org/10.1182/blood-2022-166991

Scalia, S., Toskic, D., Zhou, P., Mansukhani, M. M., Lee, L., Wong, S. W., Tuchman, S. A., Hoffman, J. E., Fogaren, T., Varga, C., Lentzsch, S., & Comenzo, R. (2022). The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients. Blood, 140(Supplement 1), 10120–10121. https://doi.org/10.1182/blood-2022-162352

Orlando, E., Ford, M., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation. Blood, 140(Supplement 1), 12085–12086. https://doi.org/10.1182/blood-2022-158050

Fu, J., Li, S., Ma, H., Yang, J., Brown, L. M., Pagnotti, G. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2022). The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease. Blood, 140(Supplement 1), 9930–9932. https://doi.org/10.1182/blood-2022-169921

Mosialou, I., Ali, A. M., Adams, R., Corper, A., Woods, C. M., Fan, X., Raza, A., & Kousteni, S. (2022). Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance. Blood, 140(Supplement 1), 2902–2902. https://doi.org/10.1182/blood-2022-167042

Breyer, L. M., Wang, H., Gu, D., Johnstone, B. H., Ma, H., Woods, E. J., & Mapara, M. Y. (2022). Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice. Blood, 140(Supplement 1), 7347–7348. https://doi.org/10.1182/blood-2022-169787

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3794–3795. https://doi.org/10.1182/blood-2022-163813

Esplin, I., Huang, Y., Bhat, S. A., Grantier, C., Grever, M. R., Hoffman, C., Kittai, A. S., Lucas, M. S., Moran, M. E., Reid, M., Suresh, S., Woyach, J. A., & Rogers, K. A. (2022). Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study. Blood, 140(Supplement 1), 4166–4168. https://doi.org/10.1182/blood-2022-167314

Schroers-Martin, J., Garofalo, A., Soo, J., Boegeholz, J., Alig, S. K., Sworder, B., Liu, C. L., Luikart, H., Gamino, G., Morales, D., Freystätter, K., Hamilton, J., Kurtz, D. M., Hollander, S., Rosenthal, D., Dhillon, G., Raikhelkar, J., Verleden, S., Nijland, M., … Alizadeh, A. A. (2022). Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders. Blood, 140(Supplement 1), 172–174. https://doi.org/10.1182/blood-2022-158647

Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969

Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D’Rozario, J., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Panchal, A., Lu, T., Wu, J. Q., Jiang, Y., Lefebure, M., … Kater, A. P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 140(8), 839–850. https://doi.org/10.1182/blood.2021015014

Olsen, E. A., Whittaker, S., Willemze, R., Pinter-Brown, L., Foss, F., Geskin, L., Schwartz, L., Horwitz, S., Guitart, J., Zic, J., Kim, Y. H., Wood, G. S., Duvic, M., Ai, W., Girardi, M., Gru, A., Guenova, E., Hodak, E., Hoppe, R., … Scarisbrick, J. (2022). Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, 140(5), 419–437. https://doi.org/10.1182/blood.2021012057

Alvarez, S., da Silva Almeida, A. C., Albero, R., Biswas, M., Barreto-Galvez, A., Gunning, T. S., Shaikh, A., Aparicio, T., Wendorff, A., Piovan, E., Van Vlierberghe, P., Gygi, S., Gautier, J., Madireddy, A., & A. Ferrando, A. (2022). Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair. Blood, 139(23), 3418–3429. https://doi.org/10.1182/blood.2021014103

Antoszewski, M., Fournier, N., Ruiz Buendía, G. A., Lourenco, J., Liu, Y., Sugrue, T., Dubey, C., Nkosi, M., Pritchard, C. E. J., Huijbers, I. J., Segat, G. C., Alonso-Moreno, S., Serracanta, E., Belver, L., Ferrando, A. A., Ciriello, G., Weng, A. P., Koch, U., & Radtke, F. (2022). Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL. Blood, 139(16), 2483–2498. https://doi.org/10.1182/blood.2021012077

Akkari, Y. M. N., Baughn, L. B., Dubuc, A. M., Smith, A. C., Mallo, M., Dal Cin, P., Diez Campelo, M., Gallego, M. S., Granada Font, I., Haase, D. T., Schlegelberger, B., Slavutsky, I., Mecucci, C., Levine, R. L., Hasserjian, R. P., Solé, F., Levy, B., & Xu, X. (2022). Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 139(15), 2273–2284. https://doi.org/10.1182/blood.2021014309

Wontakal, S. N., Britto, M., Zhang, H., Han, Y., Gao, C., Tannenbaum, S., Durham, B. H., Lee, M. T., An, X., & Mishima, M. (2022). RACGAP1 variants in a sporadic case of CDA III implicate the dysfunction of centralspindlin as the basis of the disease. Blood, 139(9), 1413–1418. https://doi.org/10.1182/blood.2021012334

Bonfiglio, F., Bruscaggin, A., Guidetti, F., Terzi di Bergamo, L., Faderl, M., Spina, V., Condoluci, A., Bonomini, L., Forestieri, G., Koch, R., Piffaretti, D., Pini, K., Pirosa, M. C., Cittone, M. G., Arribas, A., Lucioni, M., Ghilardi, G., Wu, W., Arcaini, L., … Rossi, D. (2022). Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 139(5), 732–747. https://doi.org/10.1182/blood.2021012386

Miller, P. G., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., Miller, B. C., Shi, W., Viswanathan, K., Leventhal, M., Werner, L., Moll, M., Cade, B. E., Barr, R. G., … Correa, A. (2022). Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood, 139(3), 357–368. https://doi.org/10.1182/blood.2021013531